Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0P6ZH
|
|||
| Former ID |
DAP001261
|
|||
| Drug Name |
Lercanidipine
|
|||
| Synonyms |
Lercanil; Masnidipine; Lercanidipine [INN]; Lercanidipine (INN); Lercanil (TN); REC 15-2375; Zanidip (TN); REC-15-2375; Methyl-1,1-dimethyl-2-(N-(3,3-diphenylpropyl)-N-methylamino)ethyl-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; (+-)-2-((3,3-Diphenylpropyl)methylamino)-1,1-dimethylethyl methyl1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; 1-[(3,3-diphenylpropyl)(methyl)amino]-2-methylpropan-2-yl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 3-[2-[(3,3-diphenylpropyl)methylamino]-1,1-dimethylethyl] 5-methyl ester; 5-O-[1-[3,3-diphenylpropyl(methyl)amino]-2-methylpropan-2-yl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hypertension [ICD-11: BA00-BA04; ICD-9: 401] | Approved | [1] | |
| Therapeutic Class |
Antihypertensive Agents
|
|||
| Company |
Forest Laboratories
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C36H41N3O6
|
|||
| Canonical SMILES |
CC1=C(C(C(=C(N1)C)C(=O)OC(C)(C)CN(C)CCC(C2=CC=CC=C2)C3=CC=CC=C3)C4=CC(=CC=C4)[N+](=O)[O-])C(=O)OC
|
|||
| InChI |
1S/C36H41N3O6/c1-24-31(34(40)44-6)33(28-18-13-19-29(22-28)39(42)43)32(25(2)37-24)35(41)45-36(3,4)23-38(5)21-20-30(26-14-9-7-10-15-26)27-16-11-8-12-17-27/h7-19,22,30,33,37H,20-21,23H2,1-6H3
|
|||
| InChIKey |
ZDXUKAKRHYTAKV-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 100427-26-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7979749, 8189996, 14789544, 43122606, 46508865, 50031840, 50112745, 50869364, 57315788, 81041038, 90340703, 92714226, 94569161, 96024801, 103555999, 104334871, 117381246, 117883634, 125336405, 126624317, 126655557, 126683225, 131292794, 131853865, 134222576, 134338497, 135023484, 137129218, 137349412, 160963873, 162180967, 164811647, 164814801, 166232226, 179149451, 184015929, 196111935, 206246033, 210279767, 210282090, 223484459, 223652700, 224044353, 226413385, 232529390, 251916783, 251918022, 252110275, 252359218, 252455991
|
|||
| ChEBI ID |
CHEBI:135930
|
|||
| ADReCS Drug ID | BADD_D01255 | |||
| SuperDrug ATC ID |
C08CA13
|
|||
| SuperDrug CAS ID |
cas=100427267
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) | Target Info | Blocker | [2] |
| KEGG Pathway | MAPK signaling pathway | |||
| Cardiac muscle contraction | ||||
| Adrenergic signaling in cardiomyocytes | ||||
| Oxytocin signaling pathway | ||||
| Hypertrophic cardiomyopathy (HCM) | ||||
| Arrhythmogenic right ventricular cardiomyopathy (ARVC) | ||||
| Dilated cardiomyopathy | ||||
| Panther Pathway | Muscarinic acetylcholine receptor 2 and 4 signaling pathway | |||
| WikiPathways | Arrhythmogenic Right Ventricular Cardiomyopathy | |||
| miR-targeted genes in muscle cell - TarBase | ||||
| miR-targeted genes in lymphocytes - TarBase | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Fixed-dose combination lercanidipine/enalapril. Drugs. 2007;67(1):95-106; discussion 107-8. | |||
| REF 2 | Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine Expert Opin Drug Metab Toxicol. 2009 Aug;5(8):981-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.